How to manage infections in the era of biologics?

Dermatologic Therapy

Volumn 21, Issue 3, 2008, Pages 180-186

  Saraceno, Rosita ^b   Chimenti, Sergio ^a,b  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Biologics; Infections; TNF antagonism

Indexed keywords

ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; EFALIZUMAB; ETANERCEPT; FLUCONAZOLE; INFLIXIMAB; ISONIAZID; LAMIVUDINE; MACROLIDE; OMALIZUMAB; RIFAMPICIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ASTHMA; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PRACTICE; DRUG SCREENING; EPIDIDYMITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPETENT CELL; INJECTION SITE PAIN; LISTERIA MONOCYTOGENES; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PSORIASIS; PYELONEPHRITIS; REVIEW; SEPSIS; SIALOADENITIS; SIDE EFFECT; SKIN LYMPHOMA; T CELL LYMPHOMA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTI-INFECTIVE AGENTS; ANTIGENS, CD; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; PATIENT SELECTION; RISK ASSESSMENT; SKIN DISEASES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45149088477     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.00189.x     Document Type: Review

References (35)

1. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003 : 48 : 3013 3022.
2. Soda R, Costanzo A, Cantonetti M, Orlandi A, Bianchi L, Chimenti S. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001 : 81 : 207 208.
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 : 350 : 2572 2581.
4. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2007 : 2007 : 332 338.
5. Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001 : 68 : 292 294.
6. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 : 105 : 3768 3785.
7. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006 : 43 : 16 24.
8. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003 : 101 : 3413 3415.
9. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004 : 89 : 1248 1252.
10. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004 : 59 : 709 717.
11. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007 : 99 : 190 193.
12. Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007 : 37 : 197 207.
13. Dubertret L, Sterry W, Bos JD, et al. CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 : 155 : 170 181.
14. Costanzo A, Peris K, Talamonti M, et al. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007 : 156 : 17 23.
15. Langley RG, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005 : 27 : 1317 1328.
16. Scheinfeld N. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis. J Dermatolog Treat 2007 : 18 : 197 208.
17. Kupper TS. Immunologic targets in psoriasis. N Engl J Med 2003 : 343 : 1987 1990.
18. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? Rheumatol Suppl 2005 : 74 : 35 39.
19. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000 : 161 : S221 S24.
20. Raychaudhuri S, Shmerling R, Ermann J, Helfgott S. Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis. Rheumatology 2007 : 46 : 887 888.
21. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007 : 27 : 1143 1148.
22. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002 : 46 : 2565 2570.
23. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004 : 16 : 393 398.
24. Symmons DP, Silman A. The world of biologics. Lupus 2006 : 15 : 122 126.
25. Geraghty EM, Ristow B, Gordon SM, Aronowitz P. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin Infect Dis 2007 : 44 : 82 84.
26. Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax 2007 : 62 : 1013 1014.
27. Kesteman T, Yombi JC, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol 2007 : 26 : 2173 2175.
28. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006 : 43 : 95 100.
29. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2007.
30. Muñoz P, Giannella M, Valerio M, et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis 2007 : 57 : 443 446.
31. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis 2006 : 43 : 19 22.
32. Sawalha AH, Lutz BD, Chaudhary NA, Kern W, Harley JB, Greenfield RA. Panniculitis: a presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol 2003 : 9 : 259 262.
33. Borrás-Blasco J, Nuñez-Cornejo C, Gracia-Perez A, et al. Parapharyngeal abscess in a patient receiving etanercept. Ann Pharmacother 2007 : 41 : 341 344.
34. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005 : 3 : 599 606.
35. Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006 : 55 : 429 437.